Parabilis reports Q3 2026 results, aligns with FDA on desmoid Phase 3 designNov 12Quarterly updateParabilis Medicines, Inc.
Parabilis Medicines to present zolucatetide desmoid tumor data at ESMO Congress 2026Sep 15Clinical readoutParabilis Medicines, Inc.
Parabilis Medicines' chief medical officer to depart in SeptemberSep 2PeopleParabilis Medicines, Inc.
Parabilis Medicines adds oncology veteran Craig Tendler to boardAug 25PeopleParabilis Medicines, Inc.TuHURA Biosciences, Inc
Parabilis reports Q2 2026 results, $1.1B cash, Regeneron pactAug 13Quarterly updateParabilis Medicines, Inc.